1213 related articles for article (PubMed ID: 26149712)
1. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
2. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Morgan G; Palumbo A; Dhanasiri S; Lee D; Weisel K; Facon T; Delforge M; Oriol A; Zaki M; Yu X; Sternas L; Jacques C; Akehurst R; Offner F; Dimopoulos MA
Br J Haematol; 2015 Mar; 168(6):820-3. PubMed ID: 25403264
[TBL] [Abstract][Full Text] [Related]
3. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Richardson PG; Siegel DS; Vij R; Hofmeister CC; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N; Song K; Belch A; Raje N; Shustik C; Lentzsch S; Lacy M; Mikhael J; Matous J; Vesole D; Chen M; Zaki MH; Jacques C; Yu Z; Anderson KC
Blood; 2014 Mar; 123(12):1826-32. PubMed ID: 24421329
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Weisel K; Dimopoulos M; Moreau P; Yagci M; Larocca A; Kanate AS; Vural F; Cascavilla N; Basu S; Johnson P; Byeff P; Hus M; Rodríguez-Otero P; Muelduer E; Anttila P; Hayden PJ; Krauth MT; Lucio P; Ben-Yehuda D; Mendeleeva L; Guo S; Yu X; Grote L; Biyukov T; Dhanasiri S; Richardson P
Leuk Lymphoma; 2020 Aug; 61(8):1850-1859. PubMed ID: 32268815
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
[TBL] [Abstract][Full Text] [Related]
9. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
[TBL] [Abstract][Full Text] [Related]
10. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Moreau P; Weisel KC; Song KW; Gibson CJ; Saunders O; Sternas LA; Hong K; Zaki MH; Dimopoulos MA
Leuk Lymphoma; 2016 Dec; 57(12):2839-2847. PubMed ID: 27173785
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Alegre A; Oriol-Rocafiguera A; Garcia-Larana J; Mateos MV; Sureda A; Martinez-Chamorro C; Cibeira MT; Aguado B; Knight R; Rosettani B
Leuk Lymphoma; 2012 Sep; 53(9):1714-21. PubMed ID: 22292853
[TBL] [Abstract][Full Text] [Related]
12. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A
Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016
[TBL] [Abstract][Full Text] [Related]
16. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
Mushtaq A; Iftikhar A; Hassan H; Lakhani M; Sagar F; Kamal A; Zahid U; Ali Z; Razzaq F; Zar MA; Hassan SF; Safdar A; Raychaudhuri S; Anwer F
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):447-461. PubMed ID: 31060991
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
Baertsch MA; Schlenzka J; Mai EK; Merz M; Hillengaß J; Raab MS; Hose D; Wuchter P; Ho AD; Jauch A; Hielscher T; Kunz C; Luntz S; Klein S; Schmidt-Wolf IG; Goerner M; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Salwender H; Scheid C; Nogai A; Haenel M; Lindemann HW; Martin H; Noppeney R; Weisel K; Goldschmidt H
BMC Cancer; 2016 Apr; 16():290. PubMed ID: 27114074
[TBL] [Abstract][Full Text] [Related]
20. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
